Mice Model Market 2034: Size, Trends, Key Drivers, and Analysis

New York, January 5, 2026

Charles River Laboratories International, Inc. (NYSE: CRL), a global leader in preclinical services and mice model solutions, today announced the launch of advanced humanized mouse models designed to accelerate oncology drug discovery. These innovative strains incorporate human immune system components, offering researchers unprecedented accuracy in simulating human tumor responses.

Get a PDF Copy: https://www.theinsightpartners.com/sample/TIPRE00022453

The new models build on recent breakthroughs in CRISPR technology, addressing key challenges in translating preclinical results to clinical success. By mimicking human biology more closely, they support faster development of targeted therapies amid rising demand for personalized medicine.

Industry Momentum

Recent developments underscore the dynamic evolution of the mice model market. Charles River enhanced its International Genetic Standardization program with immunodeficient and transgenic strains, including rasH2 models for carcinogenicity testing. The Jackson Laboratory introduced the CAST/EiJ strain for COVID-19 research and new models for alternating hemiplegia and late-onset Alzheimer's using CRISPR. Envigo expanded with B-NDG hIL15 mice for NK-cell studies and acquired Horizon Discovery's research models unit.

These innovations reflect broader trends where gene-editing tools like CRISPR enable precise disease modeling for cancer, immunology, and infectious diseases. Leading providers such as Taconic Biosciences, GenOway, and Crown Bioscience continue to drive progress through specialized offerings.

Market Analysis and Forecast

The mice model market supports critical biomedical research, with growth fueled by pharmaceutical pipelines and chronic disease studies. Projections indicate steady expansion through 2031, driven by demand for genetically engineered and humanized models.

Global Trends: Advancements in CRISPR and stem cell technologies boost model precision, while rising oncology and neurology research propels adoption; forecasts show compound annual growth around 6-10% through 2031.

Market Size: According to The Insight Partners, The Mice Model Market size is forecast to experience steady expansion, projected to reach US$ 3.29 billion by 2034, rising from US$ 2.00 billion in 2025. The market is anticipated to register a Compound Annual Growth Rate (CAGR) of 5.75% during the forecast period of 2026-2034.

For More Info: https://www.theinsightpartners.com/reports/mice-model-market

Share Dynamics: Oncology holds a dominant share due to personalized therapy needs; immunology and metabolic studies gain traction.

Key Drivers: Preclinical drug testing mandates, personalized medicine rise, and biotech expansion; opportunities in humanized models for immunotherapy.

Challenges: Ethical concerns and alternative methods like organ-on-chip temperature growth, yet in vivo relevance sustains demand.

Global and Regional Insights

North America commands the largest share, supported by robust pharma infrastructure, NIH funding, and biotech hubs. Europe emphasizes standardized models via programs like Horizon Europe, focusing on rare diseases.

Asia-Pacific exhibits the fastest growth, with China, India, and Japan investing in research centers and domestic pharma. Emerging regions like South America and the Middle East & Africa see potential through infectious disease studies and facility builds.

Purchase a Copy of this report at: https://www.theinsightpartners.com/buy/TIPRE00022453

Strategic Implications

These models integrate seamlessly into drug discovery workflows, from breeding to phenotyping. Charles River's end-to-end services, including cryopreservation, genetic testing, and quarantine, ensure reliability. Researchers benefit from reduced timelines and higher translational success rates.

Key applications span oncology, immunology, CNS, and metabolic studies, and outbred strains complementing engineered ones. The shift toward outsourced models optimizes costs for pharma and CROs.

Contact Us

Email: sales@theinsightpartners.com
Website: www.theinsightpartners.com
Phone: +1-646-491-9876

About The Insight Partners

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, and Chemicals and Materials.

This release was published on openPR.